Trial · NCT01739348
Adverse events3,160
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 3,160
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Arm A. Verubecestat 12 mg [Part I] | 8 | 702 | 8 |
| other | Anaemia | Blood and lymphatic system disorders | Arm B. Verubecestat 40 mg [Part I] | 11 | 700 | 11 |
| other | Anaemia | Blood and lymphatic system disorders | Arm C. Verubecestat 60mg/40mg [Part I] | 1 | 103 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Arm D. Placebo [Part I] | 6 | 705 | 6 |
| other | Anaemia | Blood and lymphatic system disorders | Arm A. Verubecestat 12 mg [Part II] | 5 | 379 | 5 |
| other | Anaemia | Blood and lymphatic system disorders | Arm B. Verubecestat 40 mg [Part II] | 1 | 365 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Arm C. Verubecestat 40 mg [Part II] | 4 | 61 | 5 |
| other | Anaemia | Blood and lymphatic system disorders | Arm D. Verubecestat 40 mg [Part II] | 5 | 394 | 5 |
| other | Constipation | Gastrointestinal disorders | Arm A. Verubecestat 12 mg [Part I] | 30 | 702 | 32 |
| other | Constipation | Gastrointestinal disorders | Arm B. Verubecestat 40 mg [Part I] | 27 | 700 | 29 |
| other | Constipation | Gastrointestinal disorders | Arm C. Verubecestat 60mg/40mg [Part I] | 9 | 103 | 9 |
| other | Constipation | Gastrointestinal disorders | Arm D. Placebo [Part I] | 20 | 705 | 20 |
| other | Constipation | Gastrointestinal disorders | Arm A. Verubecestat 12 mg [Part II] | 13 | 379 | 14 |
| other | Constipation | Gastrointestinal disorders | Arm B. Verubecestat 40 mg [Part II] | 3 | 365 | 3 |
| other | Constipation | Gastrointestinal disorders | Arm C. Verubecestat 40 mg [Part II] | 4 | 61 | 5 |
| other | Constipation | Gastrointestinal disorders | Arm D. Verubecestat 40 mg [Part II] | 10 | 394 | 10 |
| other | Diarrhoea | Gastrointestinal disorders | Arm A. Verubecestat 12 mg [Part I] | 56 | 702 | 65 |
| other | Diarrhoea | Gastrointestinal disorders | Arm B. Verubecestat 40 mg [Part I] | 60 | 700 | 70 |
| other | Diarrhoea | Gastrointestinal disorders | Arm C. Verubecestat 60mg/40mg [Part I] | 4 | 103 | 9 |
| other | Diarrhoea | Gastrointestinal disorders | Arm D. Placebo [Part I] | 42 | 705 | 45 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01739348/events